[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"weight-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:weight-loss":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,83,0,25,[9,46,76,99,122,177,197,215,248,272,294,321,371,395,419,442,481,515,546,569,590,636,657,687,710],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100594129","randomized-study-on-transoral-outlet-reduction-and-lifestyle-changes-for-weight-regain-after-gastric-bypass-100594129",false,"NCT07015424","Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass","Prospective, Randomized Clinical Study Evaluating Transoral Outlet Reduction (TORe) and Lifestyle Modification for Patients With Weight Regain Following Roux-en-Y Gastric Bypass","REIGNITE","Inclusion Criteria:\n\n* 18 years or older.\n* Experiencing weight regain (≥ 20% weight from nadir) after achieving clinically successful weight loss.\n* Willing to have a TORe procedure for the treatment of weight regain.\n* BMI between 30 and 50 kg\u002Fm2, inclusive.\n* GJA diameter ≥ 20 mm, confirmed either during a\n* Screening EGD completed ≤ 60 days from study procedure or\n* EGD performed immediately prior to the TORe procedure.\n* Anatomically accepting of the procedure, including a pouch size that will not require reduction at the time of treatment (pouch that is shorter than 6 cm in length).\n* Agrees not to take additional over the counter or prescribed weight loss supplements \u002F medications (including incretins) during the first 6 months of the study.\n* Is on a stable dose of anti-diabetic medication for three months with no anticipated changes during the first 6 months of the study.\n* Agrees to the follow-up requirements of the study and is able to read, understand, and sign a written Informed Consent Form to participate in the study.\n* Meets the indications for TORe procedure with OverStitch™ Endoscopic Suturing System.\n\nExclusion Criteria:\n\n* Current use or use within the three months prior to the baseline visit of over the counter or prescribed weight loss supplements \u002F medications (including incretins).\n* Current or planned management of Type 2 Diabetes with incretin medications.\n* Inability or unwillingness to comply with assigned treatment or protocol requirements related to visits.\n* Investigator's medical judgement that the subject is not a candidate for the TORe procedure.\n* Current pregnancy confirmed by site standard of care or planned pregnancy or breastfeeding in the next two years.\n* Vulnerable subject.","ALL","18 Years",{"count":21,"type":22},108,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to evaluate weight loss with TORe and intensive lifestyle modification versus intensive lifestyle modification alone in subjects who have regained weight following a Roux-en-Y gastric bypass.\n\nParticipants will randomized 2:1. Those randomized to the TORe arm will receive a TORe procedure and intensive lifestyle modification which consists of a well-balanced calorie restrictive diet, incorporation of exercise and coaching on lifestyle discussion. Participants randomized the lifestyle modification alone arm will be eligible to receive a TORe procedure at 6 months post enrollment. Total follow up will be 24 months.",[28,29],"Weight Regain","Weight Loss",[31,32],"TORe","OverStitch","RECRUITING","2026-08-17",{"date":36,"type":37},"2026-08-19","ACTUAL",{"date":39,"type":37},"2026-04-14",{"date":41,"type":22},"2028-11",{"name":43,"class":44},"Boston Scientific Corporation","INDUSTRY",9,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100617566","effects-of-multi-strain-bacillus-spore-probiotics-on-growth-digestive-function-and-gut-microbiota-in-cesarean-delivered-neonates-100617566","NCT07320287","Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates","A Randomized, Blinded, Controlled Trial to Evaluate Effects of Multi-strain Bacillus Spore Probiotic Supplements (LiveSpo PREG-MOM and LiveSpo CONSY) on Growth Metrics, Prevention of Functional Gastrointestinal Disorders, and Modulation of the Gut Microbiota in Cesarean-Delivered Neonates","Inclusion Criteria:\n\n* Healthy term neonates delivered by cesarean section.\n* Infants were born at term, ranging from 38 to 40 weeks' gestation.\n* Birth weight appropriate for gestational age (AGA), defined as between the 10th and 90th percentiles for gestational age (≥P10 and ≤P90).\n* The infant's parent(s) or legal guardian(s) provide written informed consent and agree to comply with study procedures.\n\nExclusion Criteria:\n\nFor the neonate:\n\n* Multiple births (twins, triplets, etc.)\n* Birth weight outside the appropriate-for-gestational-age range: small for gestational age (SGA, \\\u003C P10) or large for gestational age (LGA, \\> P90).\n* Major congenital abnormalities affecting the hematologic, hepatobiliary, cardiovascular, renal\u002Furinary, or gastrointestinal systems; severe inborn errors of metabolism; or suspected primary immunodeficiency.\n* Prior exposure to systemic or enteral antibiotics (oral, IV, or IM) before the baseline assessment.\n* Known allergy or intolerance to any component of the investigational product.\n* Concurrent participation in another interventional clinical trial.\n* The investigators judge the neonate to be unsuitable for participation.\n* Parent(s) or legal guardian(s) who do not comply with study requirements or refuse to sign the informed consent.\n\nFor the mother:\n\n* Mother diagnosed with a serious or unstable medical condition involving the hepatobiliary, renal\u002Furinary, cardiovascular, respiratory, endocrine\u002Fmetabolic, or psychiatric systems.\n* Mother who intends to use, or is prescribed, any other probiotic\u002Fprebiotic product for herself or the infant during the study period.",true,"0 Days","1 Day",{"count":57,"type":22},180,[25],"Infants born by cesarean section commonly show early weight loss and slower recovery of birth weight, together with characteristic patterns of gut microbiota dysbiosis marked by reduced Bifidobacterium and Bacteroides and increased Proteobacteria. This early microbial alteration has been associated with functional gastrointestinal disorders (FGIDs), including colic, regurgitation, and changes in stool frequency and consistency, which may in turn affect early growth and overall gastrointestinal functioning. Probiotic supplementation is considered a safe and feasible strategy to support microbial restoration and improve digestive function during the first months of life.\n\nIn this study, researchers propose that daily supplementation with multi-strain Bacillus spore probiotics may help support healthy early growth, reduce functional gastrointestinal symptoms, and promote a more balanced gut microbiota in cesarean-delivered infants.\n\nThe objective of this study is to evaluate the safety and efficacy of two oral probiotic formulations, LiveSpo PREG-MOM and LiveSpo CONSY, containing multi-strain B. subtilis ANA46, B. clausii ANA39, and B. coagulans ANA40 at respective 3 and 4 billion colony-forming units (CFU)\u002F5 mL ampoule, administered 1 ampoule daily, during the first 90 days of life. The study examines effects on growth, digestive symptoms, immune markers, and microbial composition.\n\nStudy Design: This randomized, blind, controlled clinical trial will enroll 180 healthy full-term cesarean-born infants at Hanoi Obstetrics and Gynecology Hospital.\n\nIntervention Description: Participants will be randomly assigned to three groups (n = 60 each). All groups will receive one 5-mL ampoule daily for 90 days: LiveSpo PREG-MOM, LiveSpo CONSY, or placebo. Stool samples will be collected at several follow-up time points to assess digestive health and microbial development. All products will be provided in blinded and coded packaging to maintain objectivity.\n\nStudy Duration: 12 months",[61,29],"Functional Gastrointestinal Disorders (FGIDs)",[63,64,65],"Cesarean-born Infants","Gut Dysbiosis","Bacillus spore","2026-08-12",{"date":68,"type":37},"2026-08-13",{"date":70,"type":37},"2026-01-26",{"date":72,"type":22},"2027-01-07",{"name":74,"class":44},"Anabio R&D",1,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":53,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":75},"100568439","the-role-of-microbiome-in-recurrent-obesity-before-and-after-antibioticplacebo-treatment-100568439","NCT06681246","The Role of Microbiome in Recurrent Obesity Before and After Antibiotic\u002FPlacebo Treatment","Inclusion Criteria:\n\n* 28 \\\u003C BMI\\\u003C 40\n* Age - 18-65\n* Capable of working with a smartphone application\n\nExclusion Criteria:\n\n* Consumption of antibiotics\u002Fprobiotics\u002Foral antifungals 2 months prior to the first day of the experiment.\n* Pregnancy, fertility treatments, breastfeeding women six months prior to enrollment and during the study.\n* Chronic disease, to the discretion of the study team (e.g. AIDS, Cushing syndrome, CKD, acromegaly etc.)\n* Cancer and recent anticancer treatment\n* Psychiatric disorders, to the discretion of the study team.\n* Coagulation disorders\n* IBD (inflammatory bowel diseases)\n* Bariatric surgery.\n* Eating disorders (Anorexia nervosa. Bulimia nervosa. Binge eating disorder, Night eating syndrome).\n* Alcohol or substance abuse\n* Weight loss attempts 6 months prior to the first day of the experiment - using weight loss medication.\n* Drastic changes in nutritional habits six months prior to the first day of the study - to the discretion of the study team.\n* Allergy to penicillin.\n* Life threatening reaction after consumption of cephalosporins.\n* History of CDI\n* Liver disease\n* History of serious unresolved diarrhea in response to antibiotic treatment to the discretion of the study doctor.","65 Years",{"count":84,"type":22},200,[25],"This past century witnessed a significant increase in the prevalence of obesity. Successful weight loss maintenance is defined as losing at least 10% of the initial body weight and maintaining it for at least one year. However, keeping a low body weight is rarely maintained, as 80% of people who lost 10% of their body weight will return to their initial weight within a year. Although there is no agreement as to what contributes to the recurrent weight regain phenomenon (also known as 'weight cycling' or 'yo-yo diet'), it is strongly associated with the risk of developing metabolic risk factors and their complications, including heart disease and all-cause mortality. Altering the gut microbiota is one method to treat disease states associated with gut bacteria. Antibiotics consumption is known to influence host glycemic response through changes induced in microbiome composition and function. Therefore, it may be a possible pathway to jumpstart changes in the gut microbiota.\n\nThis study will determine whether microbiome modulation might be a possible future target against recurrent obesity in humans and whether orally administered antibiotic treatment post-weight loss might be an effective intervention to prevent weight regain.",[88,29],"Obesity","2026-08-09",{"date":91,"type":37},"2026-08-11",{"date":93,"type":37},"2024-12-11",{"date":95,"type":22},"2027-12",{"name":97,"class":98},"Weizmann Institute of Science","OTHER",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":118,"leadSponsor":120,"locationsCount":75},"100566725","planning-grant-for-tops-for-breast-cancer-survivors-100566725","NCT06658912","Planning Grant for TOPS for Breast Cancer Survivors","Planning Grant for Take Off Pounds Sensibly (TOPS) Classes for Breast Cancer Survivors","Aim 2 Inclusion Criteria:\n\n* women diagnosed with breast cancer with BMI ≥ 25 kg\u002Fm2 after completion of primary therapy (surgery, radiation, adjuvant or neo-adjuvant chemotherapy).\n\nAim 2 Exclusion Criteria:\n\n* Those whose oncology providers do not agree with their participation in a weight loss program\n* History of Type II Diabetes Mellitus\n* those participating in another weight loss program\n* those taking a weight loss medication\n* those without smart phones or internet connections or the ability to attend meetings via Zoom","FEMALE","21 Years","90 Years",{"count":7,"type":22},[25],"The purpose of this study is to help make a community led weight loss program known as Take Off Pounds Sensibly (TOPS) more relevant for breast cancer survivors.\n\nThis study is made up to two parts. The first part includes using focus groups to review current materials that the investigators plan to use in upcoming TOPS classes and provide feedback. Focus groups will be made up of women who are breast cancer survivors.\n\nThe second part includes taking the feedback received from these focus groups and use this feedback to tailor TOPS classes for breast cancer survivors.\n\nThis ClinicalTrials.gov record is specific to the second part of the study.",[113,29],"Breast Cancer","2026-08-03",{"date":116,"type":37},"2026-08-05",{"date":114,"type":37},{"date":119,"type":22},"2027-09-30",{"name":121,"class":98},"Duke University",{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":75},"100595447","reset-enhancing-weight-loss-in-a-digital-intervention-100595447","NCT07032571","Reset: Enhancing Weight Loss in a Digital Intervention","Enhancing Weight Loss in a Digital Intervention Among Adults With Overweight or Obesity","Inclusion Criteria:\n\n* adults (ages 18+ years)\n* body mass index (BMI) 25.0 to 45.0 kg\u002Fm\\^2\n* cellphone ownership with a texting plan\n* daily access to a personal scale\n* daily access to a personal email account\n* English language proficiency\n* interest in losing weight through behavioral strategies\n* living in the United States\n\nExclusion Criteria:\n\n* concurrent enrollment in another weight management intervention\n* loss of ≥5% body weight in the past 6 months\n* current use of a weight loss or anti-obesity medication\n* prior or planned bariatric surgery in the next 3 months\n* current pregnancy, planned pregnancy in the next 3 months, or recent pregnancy in the past 6 months\n* current breastfeeding or lactating\n* living with someone else participating in the study\n* hospitalization for a mental health condition in the past 12 months\n* inability to engage in moderate forms of physical activity akin to brisk walking\n* if weight loss is contraindicated or might be impacted by a condition (e.g., end stage renal disease, cancer, schizophrenia, dementia) or medication (e.g., steroids, antipsychotics)\n* if an individual would be better suited for a more intensive or different type of intervention based on a health condition (e.g., individuals with history of an eating disorder or cardiovascular event, uncontrolled hypertension, or uncontrolled diabetes mellitus)\n* participation in another weight loss study conducted in Dr. Patel's lab in the past 6 months\n* investigator discretion for safety reasons",{"count":130,"type":22},208,[25],"The goal of the Reset trial is to learn about the optimal combination of dietary behavior strategies in a fully digital weight loss intervention. The intervention is designed for adults with overweight or obesity. The investigators will examine the impact on weight loss of four dietary strategies: 1) limiting Red Zone Foods (i.e., foods that are high in calories and low in nutrition), 2) limiting eating windows, 3) increasing protein intake, and 4) increasing fiber intake. Each of these strategies will include goal setting, daily self-monitoring, and tailored feedback.\n\nThe investigators will recruit 208 participants. Broadly, adults with overweight or obesity who live in the U.S. will be eligible. The weight loss intervention will last 12 weeks. All participants will be asked to track their body weight daily and complete weekly behavioral lessons and action plans to promote healthy eating and physical activity. All study tasks will occur remotely. Assessment of body weight and survey measures will occur at the beginning of the trial (\"baseline\"), and at 1 month and 3 months.\n\nThe Multiphase Optimization Strategy (MOST) framework will be used to identify which combination of the dietary behavior strategies results in the greatest weight loss. In total, there will be 16 treatment conditions.",[88,134,29,135,136],"Overweight","Health Behavior","Lifestyle Intervention",[138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166],"obesity","overweight","weight loss","weight","health behavior","lifestyle intervention","lifestyle modification","multiphase optimization strategy","intervention","behavior change","weight reduction","lose weight","adults","BMI reduction","body fat reduction","weight control","weight change","weight management","obesity management","obesity treatment","digital health","digital intervention","remote intervention","standalone intervention","obesity prevention","diabetes prevention","mobile health","factorial design","intervention optimization","NOT_YET_RECRUITING","2026-08-01",{"date":170,"type":37},"2026-08-04",{"date":172,"type":22},"2026-09",{"date":174,"type":22},"2027-03",{"name":176,"class":98},"Stanford University",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100614224","overstitch-nxt-endoscopic-suture-system-100614224","NCT07276815","OverStitch NXT Endoscopic Suture System","Gathering of Results in Eligible Asian Obese Populations About Safety and Effectiveness of Overstitch ESG Trial","Inclusion Criteria:\n\n1. Aged 18 years or older, or subjects who have reached the legal age for signing informed consent in accordance with local laws and regulations.\n2. BMI ≥ 32.5 kg\u002Fm²; or BMI ≥ 27.5 kg\u002Fm² combined with type 2 diabetes mellitus (regardless of the effectiveness of medical treatment for type 2 diabetes); or BMI between 27.5 kg\u002Fm² and 32.5 kg\u002Fm² with ineffective medical weight loss or combined with other obesity-related diseases for which medical treatment is ineffective.\n3. Willing to comply with the long-term strict dietary restrictions required by the surgery.\n4. Capable of providing informed consent, able to complete all routine follow-up visits, and willing to abide by the protocol requirements, including signing the informed consent form, completing relevant examinations, and receiving dietary counseling.\n5. Females of childbearing potential (i.e., premenopausal or not sterilized) must agree to use adequate contraceptive measures.\n\nExclusion Criteria:\n\n1. History of foregut or gastrointestinal (GI) surgery (except uncomplicated cholecystectomy or appendectomy)\n2. Prior gastrointestinal surgery with sequelae, i.e. obstruction, and\u002For adhesive peritonitis or known abdominal adhesions.\n3. Prior open or laparoscopic bariatric surgery.\n4. Prior surgery of any kind on the esophagus or any type of hiatal hernia surgery.\n5. Any inflammatory disease of the gastrointestinal tract including severe (LA Grade C or D) esophagitis, gastric ulceration, duodenal ulceration, specific inflammation such as Crohn's disease, and the doctor judges that it may affect the operation or efficacy of ESG.\n6. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresia or stenosis.\n7. History of gastrointestinal stromal tumors, gastrointestinal cancer, low-grade or high-grade gastric intraepithelial neoplasia, or familial or non-familial adenomatous polyposis syndrome.\n8. Gastric masses or untreated gastric polyps with a diameter \\> 1 cm.\n9. Hiatal hernia (Z-line displacement above the diaphragm \\> 4 cm) or severe\u002Frefractory gastroesophageal reflux symptoms, which the physician judges may affect the performance or prognosis of ESG.\n10. Structural abnormalities of the esophagus or pharynx that may impede endoscopic passage (e.g., strictures or diverticula), which the physician judges may affect the performance or prognosis of ESG.\n11. Gastrointestinal motility disorders (e.g., achalasia, severe esophageal motility disorders, gastroparesis, or intractable constipation), which the physician judges may affect the performance or prognosis of ESG.\n12. Evidence of untreated psychiatric or eating disorders, such as major depression, schizophrenia, substance abuse, binge eating disorder, or bulimia nervosa.\n13. Coagulopathy with INR \\> 1.5 that cannot be corrected (per physician's judgment) or requirement for continuous full anticoagulant therapy, and\u002For any underlying diseases associated with high bleeding risk.\n14. Insulin-dependent diabetes mellitus (type 1 or type 2), or high likelihood of requiring insulin therapy within the next 12 months.\n15. Decompensated cirrhosis, or acute\u002Fchronic liver dysfunction that the physician judges make the subject unsuitable for ESG treatment.\n16. Diagnosis of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma) or immunocompromise, which the physician assesses may affect the performance or prognosis of ESG.\n17. Known history of endocrine diseases affecting body weight (e.g., Cushing's syndrome, uncontrolled hypothyroidism, or hyperthyroidism), which the physician assesses may affect the performance or prognosis of ESG.\n18. Anemia: Hemoglobin (Hgb) \\\u003C 110 g\u002FL for females; Hgb \\\u003C 120 g\u002FL for males.\n19. Any other medical conditions precluding elective endoscopy, such as poor general health, history of severe renal, hepatic, cardiac, and\u002For pulmonary diseases, and\u002For severe or uncontrolled psychiatric illnesses or abnormalities that may impair the patient's ability to understand or comply with follow-up visits and lifestyle interventions.\n20. Active psychological issues as determined by a psychologist or psychiatrist, precluding participation in lifestyle modification programs.\n21. Unwillingness to participate in the established medically supervised dietary and behavioral modification programs, as well as routine medical follow-up.\n22. Daily treatment with prescribed high-dose aspirin (\\> 80 mg per day), non-steroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, anticoagulants, corticosteroids, immunosuppressants, or other gastric irritant medications.\n23. Interval use of medications that may be affected by changes in gastric emptying (e.g., antiepileptic drugs or antiarrhythmic drugs).\n24. Inability or unwillingness to take prescribed proton pump inhibitor (PPI) medications.\n25. Current use of weight loss medications or other weight loss devices or use within the past 90 days.\n26. Current participation in a clinical trial involving investigational drugs or devices, or participation in such a trial within 30 days prior to enrollment in this study.\n27. Use of intragastric devices within 30 days prior to this study, which the physician assesses may affect the performance or prognosis of ESG.\n28. Unwillingness to avoid any reconstructive and\u002For plastic surgeries that may affect body weight during the study (e.g., mammoplasty, liposuction).\n29. Other conditions deemed unsuitable for endoscopy or ESG treatment by the investigator, including but not limited to conditions that the investigator believes may expose the subject to significant risks, confound study results, increase risks associated with endoscopy and\u002For endoscopic procedures, or substantially interfere with the subject's participation in the study.\n30. Pregnancy, lactation, or intention to become pregnant during the study (for females of childbearing potential).",{"count":185,"type":22},136,[25],"To demonstrate the safety and efficacy of OverStitch NXT Endoscopic Suture System for endoscopic sleeve gastroplasty（ESG） in obese populations to support the registration of OverStitch NXT for ESG indication.",[29],"2026-07-28",{"date":191,"type":37},"2026-07-29",{"date":193,"type":22},"2026-08-31",{"date":195,"type":22},"2029-10-31",{"name":43,"class":44},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":75},"100607988","orbera365-intragastric-balloon-system-abbreviated-asorbera365-100607988","NCT07195708","Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')","Clinical Study to Evaluate the Safety and Efficacy of the Orbera365 Intragastric Balloon System in Obese Patients","Inclusion Criteria:\n\n1. The subject is diagnosed with obesity, and the body mass index (BMI) is ≥28 kg\u002Fm² and ≤50 kg\u002Fm².\n2. The subject is aged ≥18 years.\n3. Failed previous conservative weight loss alternatives (e.g., supervised diet, exercise, and behavior modification programs).\n4. Willing to avoid the use of medical devices, medications, or other substances for weight loss purposes during the study period.\n5. Willing to avoid the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during the study period, including aspirin, diclofenac, ibuprofen, naproxen, or other known gastric-irritating drugs.\n6. Able to take proton pump inhibitors (PPIs), antiemetics, and other medications as prescribed by the researcher.\n7. Capable of walking completely independently, with no severe chronic orthopedic diseases.\n8. Willing to undergo gastroscopy.\n9. Voluntarily participate in the trial, sign the informed consent form, and be willing to comply with study requirements, including follow-ups.\n\nExclusion Criteria:\n\n1. Prior surgery involving the esophagus, stomach, and duodenum.\n2. Prior bariatric surgery or intragastric medical devices for weight loss.\n3. A large hiatal hernia of \\> 5 cm or a hernia ≤ 5 cm associated with severe or intractable gastroesophageal reflux symptoms.\n4. Patients who have a history of gastrointestinal obstruction, adhesive peritonitis.\n5. Any active inflammatory or neoplastic disease of the gastrointestinal tract. among these, inflammatory diseases include esophagitis, gastric ulcer, duodenal ulcer, and specific types (e.g., Crohn's disease), while neoplastic diseases include cancer, and the doctor judges that such conditions may affect the use of Orbera365.\n6. Potential upper gastrointestinal bleeding disorders, such as esophageal or gastric varices, congenital or acquired intestinal capillary ectasia, or other congenital gastrointestinal abnormalities, such as atresia or stenosis that precludes the usage for Orbera365.\n7. A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and\u002For an endoscope that precludes the usage for Orbera365.\n8. Achalasia, symptoms suggestive of delayed gastric emptying, or presence of any other severe motility disorder that that may pose a safety risk during placement or removal of the device.\n9. Positive result in the Helicobacter pylori breath test (Patients who turn negative after regular treatment can participate in this clinical trial).\n10. History or symptoms of uncontrolled or unstable thyroid disease.\n11. Abnormal coagulation with an INR \\> 1.5 that cannot be corrected (as judged by a physician) or requiring continuous full anticoagulant therapy, and\u002For the presence of any underlying disease associated with a high risk of bleeding.\n12. Hepatic insufficiency or liver cirrhosis, including: acute liver failure, advanced liver cirrhosis with encephalopathy, muscle atrophy, and generalized edema. severe esophageal varices with red signs and gastric varices. severe portal hypertensive gastropathy with or without gastric antral vascular ectasia.\n13. Anemia: For females, hemoglobin (Hgb) \\\u003C 110 g\u002FL. for males, hemoglobin (Hgb) \\\u003C 120 g\u002FL.\n14. Patients with known or suspected allergic reactions to the materials contained in Orbera365.\n15. Any other physical conditions that do not allow for elective endoscopy, such as poor overall health or a history and\u002For symptoms of severe kidney, liver, heart, and\u002For lung diseases. severe or uncontrolled mental illnesses or abnormalities that may affect the patient's ability to understand or comply with follow-up visits and the removal of the device 12 months later.\n16. Patients who are unable or unwilling to take the prescribed proton pump inhibitor medications during the device placement period.\n17. Patients who are unwilling to avoid any reconstructive and\u002For plastic surgeries that may affect weight during the study period, such as mammoplasty and liposuction.\n18. Patients who are unwilling to participate in the established medical supervision diet and behavior modification program and undergo regular medical follow-ups.\n19. Patients who are receiving treatment with anticoagulants, antiplatelet drugs, immunosuppressants, non-steroidal anti-inflammatory drugs (NSAIDs), or other drugs known to irritate the gastroduodenal mucosa or reduce gastrointestinal motility and\u002For are unwilling to discontinue such concomitant medications. prescription or over-the-counter weight loss drugs, drugs known to cause significant weight gain or loss (such as anesthetics, opioids, or benzodiazepines), insulin, antiepileptic drugs, antiarrhythmic drugs (such as amiodarone). other drugs that may cause weight changes, including drugs that can significantly increase weight (such as glucocorticoids, insulin secretagogues, thiazolidinediones, atypical antipsychotics, sodium valproate, lamotrigine, antidepressants, etc.), and drugs that can significantly reduce weight (such as glucagon-like peptide-1 receptor agonists, α-glucosidase inhibitors, topiramate, fluoxetine, bupropion, zonisamide, etc.).\n20. Alcohol abuse and\u002For drug abuse.\n21. Evidence of untreated mental or eating disorders, such as major depressive disorder, schizophrenia, substance abuse, binge eating disorder, or bulimia nervosa.\n22. Poor overall health, presence of specific diseases, or situations that, in the judgment of the researcher during evaluation and\u002For device placement, may put the subject at significant risk, may confound the study results, may increase the risks associated with endoscopy and\u002For balloon placement, or may significantly interfere with the subject's participation in the study (for example, having acquired immunodeficiency syndrome or hepatitis C within the past 5 years).\n23. Pregnant, breastfeeding, or having the intention to become pregnant during the study period (for females of childbearing potential).\n24. Currently participating in a study of investigational drugs or devices, or having participated in such a study within 30 days before participating in this study.",{"count":205,"type":22},144,[25],"To demonstrate the safety and efficacy of Orbera365 in obese populations to support the registration of Orbera365.",[29],{"date":191,"type":37},{"date":211,"type":37},"2026-06-03",{"date":213,"type":22},"2028-12-31",{"name":43,"class":44},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":227,"phases":4,"briefSummary":228,"conditions":229,"keywords":234,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":75},"100590436","mitigation-of-cardiovascular-disease-risks-in-children-with-extreme-obesity-100590436","NCT06967389","Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity","Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity (MODERN)","MODERN","Inclusion Criteria:\n\n* Patient seen at University of Kentucky Pediatric High BMI Clinic\n* Diagnosis of Obesity Class 2 or 3\n* Meeting the clinical criteria for the medical intervention with semaglutide for weight loss\n\nExclusion Criteria:\n\n* Any current prescribed anti-obesity medications (AOM) such as Orlistat, Phentermine, Qsymia (Phentermine\u002FTopiramate), Liraglutide, Semaglutide, and Setmelanotide\n* Any current prescribed anti-hypertensive medications\n* Any specific end-organ acute concerns (kidney disease, liver disease, congenital disease).\n* Any active infections at enrollment.\n* Any systemic steroid use longer than 3 month use or within the last month before enrollment (not including inhaled, ophthalmic, intranasal, and topical).\n* Any limitations that would make exercise testing not possible.\n* Any congenital abnormality or genetic syndrome known to be associated with obesity\n* Pregnancy\n* Inability to receive an MRI\n* Personal or family history of medullary thyroid carcinoma (per product insert)\n* Patients with Multiple Endocrine Neoplasia syndrome type 2 (per product insert)","12 Years","17 Years",{"count":226,"type":22},50,"OBSERVATIONAL","The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are:\n\n* How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment?\n* How do risk markers of disease change over the study in the study participants who are given semaglutides to help with weight loss?\n* Are there differences in the above factors between males and females and are there key factors to help improve the outcomes?\n\nParticipants will be given semaglutide for this study. During the course of the study, participants will:\n\n* have two cardiac MRI scans OR two cardiac echocardiograms (one before starting semaglutide and one around 12 months after taking the drug)\n* have body composition and fitness levels assessed twice (before semaglutide and around 12 months after taking it) and have urine specific gravity (USG) measured\n* have extra blood drawn when labs their doctor orders are already being drawn (once at the beginning of the study, once around 6 months after enrollment, and once at the end of the study)\n* have follow up visits with the study doctor\n* be asked to take a pregnancy test if they are female and have started menstruation",[230,231,232,29,233],"Obesity and Overweight","Obese Adolescents","Weight Management","Cardiovascular Disease Risk Factor",[235,236,237,138,139,238,155,140],"semaglutide","Wegovy","Ozempic","adolescent","2026-07-20",{"date":241,"type":37},"2026-07-21",{"date":243,"type":37},"2025-06-12",{"date":245,"type":22},"2028-07",{"name":247,"class":98},"John Bauer",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":53,"sex":106,"minAge":4,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":227,"phases":4,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":75},"100648360","effects-of-glp-1-ras-on-human-lactation-outcomes-100648360","NCT07720414","Effects of GLP-1 RAs on Human Lactation Outcomes","Inclusion Criteria:\n\n* Breastfeeding mothers of single or multiple infants.\n* Milk removal at least 4x daily\n* Eligible for a GLP-1 RA administered subcutaneously (oral GLP-1 RAs contain absorption enhancers, which may drive accumulation in milk)\n* Access to a breastpump, if needed for maintaining breastfeeding behaviors.\n* Willingness to provide 1-3 oz of breastmilk per study visit.\n* Willingness to track and report body weight daily.\n* Willingness to maintain breastfeeding behaviors for the duration of the study.\n\nExclusion Criteria:\n\n* Currently taking GLP-1 RA medication or other weight loss medication\n* Induced lactation, due to unknowns regarding the durability of the mammary gland's milk production after exogenous stimulation.",{"count":255,"type":22},18,"There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk.\n\nThe main questions the study will address are:\n\n* Does GLP-1 RA-induced weight loss increase or decrease breastmilk production?\n* Does GLP-1 RA-induced weight loss affect the nutritional composition of milk, including milk fat content?\n\nResearchers will assess milk production rates before and after mothers begin taking injected GLP-1 RA medications to decrease their body weight. Weight loss will be confirmed with 7-day body weight averages.\n\nParticipants will:\n\n* Weigh themselves and report measurements daily.\n* Participate in 2-3 morning study visits over approx. 2.5-4.5 months (approx. 3-3.5hrs each).\n\nDuring each visit, participants will:\n\n* Use a study provided breastpump to express milk 3 times hourly for measurement of hourly milk production.\n* Provide 1-3 oz of milk for further study.\n* Answer questions about breastfeeding patterns.",[258,29],"Lactation",[260,261,262,29],"Breastmilk production","Breastmilk composition","GLP-1","2026-07-17",{"date":265,"type":37},"2026-07-22",{"date":267,"type":22},"2026-07",{"date":269,"type":22},"2028-06",{"name":271,"class":98},"University of Colorado, Denver",{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":278,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":292,"locationsCount":75},"100645962","high-protein-plus-resistance-training-in-glucagon-like-peptide-1-receptor-agonist-users-hustle-100645962","NCT07700030","High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)","Inclusion Criteria:\n\n* Age 30- 60 years\n* BMI 27.0-37.0 kg\u002Fm² at screening\n* English speaking (at this time, MyNetDiary, a food-logging app used for tracking protein-intake, is only set up for English, and our RDN is only capable of providing nutritional counseling in English)\n* Received a prescription for tirzepatide, a second-generation oral or injectable dual GIP\u002FGLP-1 receptor agonist (Zepbound\u002FMounjaro) that is FDA-approved for obesity; and\n\n  * Has not yet started tirzepatide and agrees to complete a 4-week run-in period at the initial dose with \\\u003C3% weight loss from baseline; OR\n  * Has initiated tirzepatide and is within the first 4 weeks at the initial dose with \\\u003C3% weight loss from pre-treatment baseline.\n* On a stable regimen for major chronic conditions (e.g., antihypertensives, lipid-lowering agents, oral antidiabetics, hypothyroidism) for ≥ 8 weeks prior to enrollment.\n* Willing and able to:\n\n  * (i) Receive high-protein diet counseling and attempt to achieve \\~2.5 g\u002Fkg FFM \u002Fday protein;\n  * (ii) Attend scheduled nutrition telehealth visits with an RDN;\n  * (iii) Medically cleared for moderate-intensity resistance training 2 days\u002Fweek (no condition that would preclude safe participation in either diet-only or diet plus resistance training).\n* Willing and able to undergo whole-body MRI at baseline and 6 months without sedation.\n* Able to understand procedures and provide written informed consent in English (at this time, MyNetDiary, a food-logging app used for tracking protein-intake, is only set up for English, and our RDN is only capable of providing nutritional counseling in English)\n\nExclusion Criteria:\n\n* Patients currently prescribed oral or injectable incretin mimetics containing GLP-1RAs, including Exenatide, Liraglutide, Lixisenatide, Dulaglutide, Semaglutide. Participants who are currently prescribed tirzepatide and have been using for \\>4 weeks will also be excluded.\n* Prior use of incretin mimetics containing GLP-1RAs with \\>3% weight loss in a 4-week period\n* Lost \\>5% body weight in the past 6 months\n* Has consistently resistance trained (\\>10 sessions) in the last year\n* Currently taking medication or supplements that have been shown to impact muscle function and muscle mass in the last 6 months\n* Participants who live outside of the tri-state area and\u002For are not willing to come to New York City for in-person visits outlined\n* Plans to be out of town more than 2 consecutive weeks or \\>6 weeks total over the next 6 months\n* Type 1 or 2 diabetes; uncontrolled diabetes (e.g., HbA1c \\> 6.4% if specified); recurrent severe hypoglycemia or hypoglycemia unawareness.\n* Moderate-to-severe chronic kidney disease (e.g., eGFR \\\u003C 45-60 mL\u002Fmin\u002F1.73 m2 final cutoff per protocol) or other renal disease\n* Decompensated cirrhosis, severe chronic liver disease, or active liver disease\n* Unstable cardiovascular disease (e.g., myocardial infarction (MI), stroke, coronary revascularization, or hospitalization for unstable angina or decompensated heart failure (HF) within \\\u003C6 months)\n* Active malignancy requiring systemic therapy in the past 6-months (excluding non-melanoma skin cancer)\n* Serious medical\u002Fpsychiatric conditions making participation unsafe or likely to impair adherence\n* Pregnant, planning pregnancy within 6 months, or breastfeeding; women of childbearing potential unwilling to use effective contraception per institutional\u002Fdrug-label guidance.\n* Conditions requiring protein restriction (e.g., advanced Chronic Kidney Disease (CKD), relevant inborn errors of metabolism).\n* Severe, poorly controlled gout\u002Fhyperuricemia\n* Significant GI disease impairing tolerance or absorption (e.g., active Inflammatory Bowel Disease (IBD) with frequent flares, short bowel syndrome, severe gastroparesis beyond expected GLP-1 effects)\n* Severe food allergies or intolerances that preclude a high-protein diet or ingestion of whey or pea protein and associated additives\u002Fingredients of the protein powders used in this study.\n* Has or previously had an eating disorder\n* Severe musculoskeletal, neuromuscular, or other conditions that preclude moderate-intensity RT\n* Advised not to exercise by their general practitioner or medical professional or refusal to obtain medical clearance if indicated by Physical Activity Readiness Questionnaire (PAR-Q) answers\n* Standard contraindications to MRI: tattoos with metallic ink, pacemaker, cerebral and\u002For cochlear implant, metal in the eye, severe claustrophobia, presence of electronic devices or ferromagnetic metallic foreign or implanted objects that could constitute a hazard, inability to lie flat, or any other contraindication for MRI.\n* Weight \\>200kg, or large body habitus which the MRI scanner cannot accommodate.\n* Inability or unwillingness to attend a reasonable proportion of RT sessions and refusal of accommodations\n* Concurrent enrollment in another weight management intervention\n* Prior bariatric surgery within the past 12 months or planned bariatric surgery within the 6-month study period.\n* Active alcohol or drug use disorder\n* Significant cognitive impairment or language barrier precluding informed consent or adherence\n* Any reason that could compromise the participants' safety, based on the judgment of the investigators and\u002For clinical coordinators.","30 Years","60 Years",{"count":281,"type":22},32,[25],"The primary objective of this study is to examine the effects of a high-protein diet (HP) paired with resistance training (RT) compared with a HP diet alone, on skeletal muscle mass (SMM) volume of the (a) quadriceps and (b) rhomboids, and upper and lower body muscle strength in adults recently prescribed tirzepatide. The secondary objectives of this study are to compare changes in resting energy expenditure (REE), adaptive thermogenesis (AT), and body adiposity (SFV, VAT, and intramuscular FF) in the quadriceps and rhomboid muscles) between the high-protein diet with RT and the high-protein diet arms at 6 months.",[29],[262,286],"tirzepatide","2026-07-07",{"date":289,"type":37},"2026-07-13",{"date":267,"type":22},{"date":95,"type":22},{"name":293,"class":98},"NYU Langone Health",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":309,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":75},"100634146","scalable-behavioral-program-for-weight-loss-maintenance-after-glp-1-and-anti-obesity-medication-discontinuation-100634146","NCT07535892","Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation","Pilot Trial of a Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation","Inclusion Criteria:\n\n* Age 18 years or older\n* Loss of ≥15% of initial body weight using anti-obesity medication\n* Discontinued anti-obesity medication within the past 4 weeks or planning to discontinue prior to randomization\n* ≤3 kg weight regain within the past 3 months\n* Willing and able to participate in a 6-month behavioral intervention, including a 10-week foundational program\n* Willing to complete study assessments at baseline, 3 months, and 6 months, including required in-person visits\n* Medical clearance for participation in moderate physical activity, dietary modification, and mind-based practices\n* Access to reliable internet for participation in virtual sessions and remote data collection\n* English fluency sufficient to complete study procedures\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Medical conditions that would preclude safe participation in physical activity, dietary changes, or mind-based practices (e.g., unstable cardiovascular disease, uncontrolled hypertension, severe orthopedic limitations, or seizure disorders not medically managed)\n* Active psychiatric conditions that would interfere with participation or safety (e.g., untreated major depression, active substance use disorder, or psychosis)\n* Pregnancy, breastfeeding, or plans to become pregnant during the study period\n* Current participation in another structured weight loss or weight maintenance program\n* Continued use of anti-obesity medication after randomization\n* Plans to initiate medications or treatments that may significantly affect body weight during the study period\n* Inability to attend required study visits or participate in virtual sessions and remote data collection\n* Any condition that, in the opinion of the investigators, would compromise participant safety or study integrity",{"count":302,"type":22},64,[25],"This study is a single-site, pilot randomized factorial trial designed to evaluate the feasibility, acceptability, participant perceptions and preliminary effects of a multi-component behavioral intervention to support weight loss maintenance following discontinuation of GLP-1 and other anti-obesity medications. The intervention includes a standardized 10-week foundational weight loss maintenance program combined with candidate support components, including medically tailored meals, YMCA membership, and a structured mind-based program. Participants will be randomized using a 2 × 2 × 2 factorial design and followed for six months. Findings from this pilot study will inform optimization of a scalable intervention for future clinical trials.",[29,306,307,308],"GLP - 1","Weight Loss Maintenance","Obesity & Overweight",[29,262,310,311],"Anti-Obesity Medication","weight loss maintenance","2026-06-23",{"date":314,"type":37},"2026-06-26",{"date":316,"type":22},"2026-11-01",{"date":318,"type":22},"2029-07-31",{"name":320,"class":98},"University of Alabama at Birmingham",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":23,"phases":330,"briefSummary":331,"conditions":332,"keywords":350,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":370},"100526751","effect-of-endoscopic-sleeve-gastroplasty-in-patients-with-obesity-and-mash-a-randomized-controlled-trial-100526751","NCT06138821","Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial","Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 (male or female)\n2. BMI ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with at least one obesity-related comorbidity\n3. Self-reported stable weight (no weight change \\>5%) for 6 months prior to the first study visit\n4. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory\u002Fimaging\u002Fadditional tests, and completing diet counseling\n5. Willingness to NOT start a new anti-obesity medication for the following 12 months\n6. Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits\n7. Ability to give informed consent\n8. Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods\n\nExclusion Criteria:\n\n1. Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)\n2. Treatment with vitamin E (at doses ≥800 IU\u002Fday), pioglitazone, obeticholic acid, or resmetirom \\\u003C90 days before the first study visit\n3. History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)\n4. Prior bariatric surgery\n5. Prior endoscopic sleeve gastroplasty\n6. Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease\n7. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses\n8. Severe gastroesophageal reflux disease (GERD)\n9. A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope.\n10. Achalasia or any other severe esophageal motility disorder\n11. Chronic abdominal pain\n12. Gastroparesis or intractable constipation\n13. Hepatic insufficiency or cirrhosis\n14. Severe coagulopathy\n15. Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%\n16. Patients on an anti-platelet agent, anticoagulant agent or chronic\u002Froutine use of NSAIDs\n17. Patients on corticosteroids, immunosuppressants, or narcotics\n18. Patients on an anti-seizure or anti-arrhythmic medication\n19. Patients who are pregnant or breastfeeding\n20. Excessive alcohol consumption (\\>20 g per day for women; \\>30 g per day for men)\n21. Active smoking\n22. History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia\n23. History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer\n24. History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease\n25. History of active malignancy\n26. History of genetic or hormonal causes for obesity, such as Prader Willi syndrome\n27. History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism\n28. Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating\n29. Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist",{"count":329,"type":22},132,[25],"Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD\u002Fmetabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.\n\nOver the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown.\n\nIn this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.",[88,333,334,335,336,337,338,339,29,340,341,342,343,344,345,346,347,348,349],"Liver Diseases","Liver Fibrosis","Liver Fat","Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","MASLD","MASH","Insulin Resistance","Insulin Sensitivity","Insulin Sensitivity\u002FResistance","Metabolic Disease","Diabetes","Diabetes Mellitus, Type 2","NASH With Fibrosis","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Fatty Liver","Non-alcoholic Steatohepatitis",[351,352,353,354,355,232,356,357,358,359,360,361,362],"Gut Hormones","Endoscopic Bariatric and Metabolic Therapy (EBMT)","Intragastric Balloon (IGB)","Endoscopic Suturing","Endoscopic Sleeve Gastroplasty (ESG)","Endoscopic Gastric Remodeling (EGR)","Endoscopic Bariatric Therapy (EBT)","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Non-Alcoholic Fatty Liver Disease (NAFLD)","Non-Alcoholic Steatohepatitis (NASH)",{"date":364,"type":37},"2026-06-25",{"date":366,"type":37},"2025-06-24",{"date":269,"type":22},{"name":369,"class":98},"Pichamol Jirapinyo, MD, MPH",2,{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":75},"100548638","phase-2-effect-of-weight-loss-on-physical-and-cardiac-performance-in-people-with-obesity-and-heart-failure-100548638","NCT06423599","Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure","FIT-HF","Inclusion Criteria:\n\n* Male or female, age ≥ 18 years at the time of signing informed consent\n* Body mass index (BMI) ≥ 30 kg\u002Fm2\n* Heart failure with New York Heart Association (NYHA)-class 1-3 and reduced ejection fraction (EF≤40%) established by either:\n\n  1. echocardiography AND\u002FOR\n  2. cardiac magnetic resonance\n* On stable optimal medical heart failure therapy for at least 4 weeks\n\nExclusion Criteria:\n\n1. Cardiovascular-related:\n\n   * Any of the following: myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within the past 6 months prior to the day of screening\n   * Planned coronary, carotid or peripheral artery revascularisation known on the day of screening\n   * Transient heart failure related to reversible mechanisms like tachycardia, sepsis, etc.\n2. Glycaemia-related:\n\n   * Type 1 diabetes\n   * Treatment with any Glucagon-Like Peptide-1 (GLP-1) agonists within 90 days prior to the day of screening\n   * Type 2 diabetes requiring other pharmacotherapy than metformin and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors\n3. General safety:\n\n   * Pregnancy or planned pregnancy\n   * History or presence of chronic pancreatitis\n   * Presence of acute pancreatitis within the past 180 days prior to the day of screening\n   * Kidney disease with eGFR \\\u003C 35ml\u002Fmin\n   * Presence or history of malignant neoplasms within the past 5 years prior to the day of screening (Basal and squamous cell skin cancer and any carcinoma in-situ are allowed)\n   * Known or suspected hypersensitivity to trial product(s) or related products",{"count":379,"type":22},100,[381,382],"PHASE2","PHASE3","The benefit of weight loss in patients with obesity and heart failure with reduced ejection fraction (HFrEF) is controversial. Semaglutide has shown cardiovascular (CV) risk-reduction and impact on CV risk factors including overweight, dysglycaemia and hypertension in subjects with type 2 diabetes (T2D). The STEP-HFpEF (Semaglutide Treatment Effect in People With Obesity and HFpEF) recently demonstrated, at 1-year, to not only reduce weight considerably, but also significantly improve health-related quality of life, functional status scores and 6-min walk distance in patients with heart failure with preserved ejection fraction (HFpEF). Also, the recently concluded SELECT trial was the first CV outcome trial with semaglutide in patients with overweight or obesity and established CV disease, including heart failure (but no T2D). Semaglutide demonstrated a 20% reduction in MACE, defined as the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.\n\nThese landmark findings have important implications for clinicians -as they mean that weight loss and\u002For semaglutide as anti-obesity pharmacotherapy could be a treatment strategy for secondary prevention of CV disease in patients with overweight or obesity.\n\nIt is, however, unknown whether weight loss with either calorie-restricted diet or semaglutide has beneficial effects in obese subjects with heart failure and reduced ejection fraction. Also it is unclear whether semaglutide has cardiovascular benefits irrespective of starting weight and amount of weight loss.\n\nPurpose: The study aims to investigate whether weight loss treatment with semaglutide is superior to weight loss with calorie-restricted diet in improving peak oxygen uptake in patients with obesity and heart failure with reduced ejection fraction.",[385,88,29,386],"Heart Failure With Reduced Ejection Fraction","Chronic Heart Failure","2026-06-22",{"date":312,"type":37},{"date":390,"type":37},"2024-04-30",{"date":392,"type":22},"2027-12-30",{"name":394,"class":98},"Jens D Hove, MD,PHD",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":405,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":75},"100424854","exercise-effects-on-adipose-tissue-structure-and-function-100424854","NCT04812314","Exercise Effects on Adipose Tissue Structure and Function","LG","Inclusion Criteria:\n\n* Age: 18-40\n* Body Mass Index: 27-45 kg\u002Fm2\n* No regularly planned exercise\u002Fphysical activity for at least 6 months\n* Women must have regularly occurring menses and must be premenopausal\n\nExclusion Criteria:\n\n* Evidence\u002Fhistory of cardiovascular or metabolic disease\n* Medications known to affect lipid or glucose metabolism, or inflammation\n* Weight instability ≥ ± 6 pounds in the last 3 months\n* Tobacco or e-cigarette users\n* Women must not be pregnant or actively lactating","40 Years",{"count":404,"type":22},46,[25],"Participants will be randomized into one of two different experimental groups: 1) Exercise group and 2) No exercise (control group). Subject participation in the study will involve a series of metabolic tests before and after participants undergo a 10% weight loss program (with or without exercise training depending on group randomization). After completing this weight loss portion of the study, participants will then be required to adhere to a high calorie diet program to regain half of the weight the participant lost - followed by the same series of metabolic tests.",[88,408,343,340,29,409],"Metabolic Syndrome","Weight Gain","2026-06-02",{"date":412,"type":37},"2026-06-04",{"date":414,"type":37},"2021-03-01",{"date":416,"type":22},"2030-03-01",{"name":418,"class":98},"University of Michigan",{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":53,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":426,"targetDuration":4,"studyType":23,"phases":428,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":75},"100634520","phase-1-a-study-to-evaluate-the-pharmacokinetics-of-hrs9531-injection-in-participants-with-mild-moderate-and-normal-hepatic-function-100634520","NCT07540754","A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function","A Multi-center, Single-dose, Parallel-group, Open-label Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function","Inclusion Criteria:\n\n1. Participants must fully understand and voluntarily sign a written informed consent form before the trial, demonstrating comprehension of the trial content, procedures, and potential adverse reactions; they must also be willing and able to comply with the protocol requirements to complete the study.\n2. Female participants of childbearing potential must have a negative baseline serum pregnancy test, must not be lactating, and must agree to use contraceptive measures and refrain from egg donation from the time of signing the informed consent form until 2 months after the last dose of the study drug; male participants with partners of childbearing potential must agree to use contraceptive measures and refrain from sperm donation from the time of signing the informed consent form until 2 months after the last dose of the study drug.\n3. Aged 18 to 65 years (inclusive), both male and female.\n4. Male participants weigh no less than 50 kg, and female participants weigh no less than 45 kg. Body mass index (BMI) is within the range of 19.0 to 40.0 kg\u002Fm² (inclusive).\n\nExclusion Criteria:\n\n1. Participation in any clinical trial of a drug or medical device within 3 months prior to dosing, or currently within the follow-up period of a clinical study or within 5 half-lives of the investigational drug (whichever is longer).\n2. Allergic constitution, including a history of severe drug allergy or drug anaphylaxis, excluding untreated asymptomatic seasonal allergies or individuals with positive skin tests only.\n3. Smokers and drinkers who are unable to abstain during the trial period; positive alcohol screening test.\n4. Drug abusers or those with a positive urine drug screening test.\n5. Blood loss or blood donation ≥400 mL within 3 months prior to dosing, or blood loss or blood donation ≥ 200 mL within 1 month prior to dosing, or receipt of a blood transfusion within 3 months prior to dosing.\n6. Undergone any surgery within 6 months prior to dosing, or planned to undergo surgical procedures during the study period.\n7. Suffering from malignant tumors, or having a history of malignant tumors within 5 years prior to screening (excluding non-melanoma skin cancer that has been treated with no signs of recurrence, and resected cervical intraepithelial neoplasia).\n8. History of severe hypoglycemia.\n9. Previous significant gastric emptying abnormalities or factors affecting gastric emptying (e.g., history of gastric bypass surgery, pyloric stenosis), or severe gastrointestinal diseases (e.g., active peptic ulcer, inflammatory bowel disease, etc.), or have undergone gastrointestinal surgery (excluding surgeries with no significant impact on gastrointestinal motility, such as removal of gastrointestinal polyps, appendectomy, hemorrhoidectomy, etc.).\n10. Anyone with factors making them unsuitable to participate in this trial evaluated by the investigator.",{"count":427,"type":22},24,[429],"PHASE1","This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild\u002Fmoderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531 Injection in these participants.",[432,29],"Diabetes Mellitus","2026-05-28",{"date":435,"type":37},"2026-06-01",{"date":437,"type":37},"2026-05-26",{"date":439,"type":22},"2027-02",{"name":441,"class":44},"Fujian Shengdi Pharmaceutical Co., Ltd.",{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":23,"phases":451,"briefSummary":452,"conditions":453,"keywords":454,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":75},"100639482","simplifying-diet-tracking-in-a-digital-weight-loss-intervention-100639482","NCT07601061","Simplifying Diet Tracking in a Digital Weight Loss Intervention","Simplifying Dietary Self-Monitoring in a Digital Weight Loss Intervention","Inclusion Criteria:\n\n* adults (ages 18+ years)\n* body mass index (BMI) 25.0 to 45.0 kg\u002Fm\\^2\n* smartphone ownership\n* willing to install a mobile app on personal smartphone\n* access to a personal email account\n* English or Spanish language proficiency\n* interest in losing weight through behavioral strategies\n* living in the United States\n* willing to be randomized\n\nExclusion Criteria:\n\n* concurrent enrollment in another weight management intervention\n* loss of ≥5% weight in the past 6 months\n* prior or planned bariatric surgery during the trial period\n* current or planned pregnancy during the trial period, or recent pregnancy in the past 6 months\n* currently breastfeeding or lactating\n* current use of anti-obesity medications\n* living with someone else participating in the study\n* hospitalization for a mental health condition in the past 12 months\n* inability to engage in moderate forms of physical activity akin to brisk walking\n* medical or psychiatric contraindication (e.g., end stage renal disease, cancer, schizophrenia, dementia, use of steroids, use of antipsychotic medication)\n* if an individual would be better suited for a more intensive or different type of intervention based on a health condition (e.g., individuals with history of an eating disorder or cardiovascular event, uncontrolled hypertension, or uncontrolled diabetes mellitus)\n* investigator discretion for safety reasons",{"count":450,"type":22},328,[25],"The purpose of this study is to compare two approaches for tracking dietary intake in a 12-month fully digital weight loss intervention: (1) Simplified approach: track Red Zone Foods (e.g., foods high in calories and low in nutritional value) vs. (2) Detailed approach: track all foods and their corresponding calories. In essence, this is a head-to-head comparison of two tracking approaches; the investigators are evaluating whether weight loss is comparable over 12 months, or whether one approach will have greater weight loss.\n\nThe investigators will recruit 328 adults. Broadly, adults with overweight or obesity who live in the United States will be eligible. The weight loss intervention will last 12 months. All participants will be asked to track their dietary intake + body weight + steps daily as well as complete weekly behavioral lessons and action plans to promote healthy eating and physical activity. All study tasks will occur remotely. Assessment of body weight and survey measures will occur at the beginning of the trial (\"baseline\"), and at 1, 6, 12, and 18 months.",[134,88,29,135,136],[159,455,147,138,456,139,457,458,459,460,461,462,463,150,146,140,464,148,155,465,466,467,468,469,470,471,472,158,164,157,156,160,161,473],"behavioral intervention","body weight","BMI","diet","tracking","track","self-monitoring","self-monitor","lifestyle","weight loss intervention","red zone foods","calorie counting","noninferiority trial","non-inferiority","comparative effectiveness trial","comparative effectiveness","RCT","randomized clinical trial","standalone","2026-05-22",{"date":433,"type":37},{"date":477,"type":22},"2027-05-01",{"date":479,"type":22},"2030-10-31",{"name":176,"class":98},{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":227,"phases":4,"briefSummary":492,"conditions":493,"keywords":496,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":75},"100640329","glp-1-medication--behavioral-health-programs-on-weight--metabolic-outcomes-flourish-and-thrive-prospective-cohort-study-100640329","NCT07588984","GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study","GLP-1 Medication & Behavioral Health on Weight and Metabolic Outcomes: FLOURISH (Functional Longitudinal Outcomes Under Intentional Small Habits) & THRIVE (Trajectories of Health, Resilience & Integrated Vitality Evaluation) Cohort Study","FLOURISH","Inclusion Criteria:\n\n* Speaks English\n* Community-dwelling, community-living status\n* Able to ambulate independently, with or without aids or devices\n* Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities\n* Provides informed consent for study participation\n* Commitment and willingness to participate, as assessed by completion of decisional balance exercise\n* Program-specific eligibility:\n* Medication arms only: Meets standard of care program enrollment criteria for GLP-1 medication. Did not add other products or programs to Noom subscription.\n* Noom Weight only: Individual who is not interested in medication\n* Education-only Control Group: Individual who is interested in weight loss who is not currently enrolled in a structured weight loss program or medication program and does not intend to for the duration of the study Free Tier only: Willingness to use Free Tier\n\nExclusion Criteria:\n\n* Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)\n* GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)\n* Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program\n* Previous or planned (during the 12-month study) bariatric surgery\n* Active eating disorder\n* Active cancer\n* Type 1 diabetes or current Insulin use\n* Currently taking a medication known to cause weight gain (e.g., antipsychotics, antidepressants, diabetes medication, or corticosteroids)\n* Depression screen results in a PHQ-8 score of 20 or greater.\n\nAll medicated arms and Noom Weight arms (only):\n\n\\- Purchased more than the base Noom program offered for participant's specific arm\n\nGLP-1 Medication Arms Only:\n\n* GLP-1 agonist use is contraindicated (per program criteria) in members with:\n* Personal or family history of medullary thyroid cancer\n* Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)\n* Personal history of Pancreatitis","64 Years",{"count":491,"type":22},2310,"This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement.\n\nFLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose).\n\nTHRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control.\n\nParticipants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.",[308,29,494,495,233],"Preventative Health","Body Weight",[262,497,141,498,499,500,501,502,235,286,503,158,140,504,505],"Microdose","body composition","metabolic","biomarkers","longevity","glucagon-like peptide-1","microdosing","behavioral health","real world evidence","2026-05-08",{"date":508,"type":37},"2026-05-15",{"date":510,"type":22},"2026-04-30",{"date":512,"type":22},"2029-05",{"name":514,"class":44},"Noom Inc.",{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":53,"sex":18,"minAge":523,"maxAge":524,"enrollmentInfo":525,"targetDuration":4,"studyType":23,"phases":527,"briefSummary":528,"conditions":529,"keywords":531,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":75},"100589043","metabolic-health-bones-and-nuts-during-weight-loss-in-adults-100589043","NCT06949280","Metabolic Health, Bones and Nuts During Weight Loss in Adults","Metabolic Health, Bones and Nuts Sources of Fatty Acids During Weight Loss in Adults","BERN","Inclusion Criteria:\n\n* Men and postmenopausal women (\\>2 years since last menses), ages 50-75 years\n* Body mass index (25-42 kg\u002Fm2) or evidence of pre-clinical obesity.\n* Agree to be randomly assigned to consume a daily peanut snack or nut-free snack for 24 weeks\n* Must attend on-site visits (about 10) in New Brunswick, NJ, USA (transportation\u002Freimbursement for travel not included)\n\nExclusion Criteria:\n\n* Peanut allergies or intolerances\n* Participants with \\>5% weight loss in the past 6 months or extreme dietary\u002Fphysical activity habits\n* An inability to follow the experimental intervention or to perform the required specimen collections.\n* Individuals with significant psychiatric or food disorders.\n* Current diagnosis, or history of cancer in past 3 years.\n* Current diagnosis or history of bone diseases, type I or II diabetes, gastrointestinal disease, hyperparathyroidism, untreated thyroid disease, significant immune, hepatic, cardiac, or renal disease.\n* Uncontrolled hypertension or hyperlipidemia in abnormal ranges.\n* History of surgery in the past 6 months or surgical procedure for weight loss in the past 3 years.\n* Regular use of medications that affect bone metabolism, including bisphosphonates or hormone replacement.\n* Regular use of medications for that affect the gastrointestinal tract including incretin mimetics, cholecystitis, urinary tract infection, severe organic diseases including coronary heart disease, myocardial infarction, infectious diseases including pulmonary tuberculosis and AIDS.\n* Antibiotic use in the past month\n* Alcohol or illicit drug abuse\n* Any other condition deemed by the Research Physician that would prevent participation in the study, e.g. participation in another clinical research project that may interfere with the results of this study.\n* Participation in another clinical interventional research trial","50 Years","75 Years",{"count":526,"type":22},44,[25],"The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain, and several dietary pattern studies indicate that nuts and legumes are associated with better bone health. In addition, our preliminary translational data indicates that a higher monounsaturated fatty acid (MUFA) intake is associated with improved bone mineral density (BMD) and quality. Given these findings, the proposed study aims to examine the impact of consuming peanut products on bone health, metabolic health (e.g., serum glucose, insulin, lipids and inflammation), markers of brain and sleep health, and physical function in overweight and obese older adults before and after a six-month weight loss intervention using a randomized controlled design. The results of this study have the potential to provide valuable insights into the role of peanuts as a sources of fatty acids in promoting health and preventing disease in at-risk adults.",[29,530,230],"Bone Density",[140,150,532,533,534,535,536,537],"bone","cognition","metabolic health","sleep","peanut","Monounsaturated fatty acid",{"date":539,"type":37},"2026-05-13",{"date":541,"type":37},"2025-10-30",{"date":543,"type":22},"2027-12-31",{"name":545,"class":98},"Rutgers, The State University of New Jersey",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":23,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":75},"100610161","phase-1-semaglutide-sema-for-alcohol-use-disorder-aud-after-metabolic-and-bariatric-surgery-mbs-100610161","NCT07223983","Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)","Semaglutide Treatment for Alcohol Use Disorder After Metabolic and Bariatric Surgery: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up)\n* Age 18 and older\n* Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg\u002Fm2\n* Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years\n* Meet current DSM-5 criteria for Alcohol Use Disorder\n* Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators\n* Read, comprehend, and write English at a sufficient level to complete study-related materials\n* For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation\n\nExclusion Criteria:\n\n* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening\n* History or presence of chronic or recurrent pancreatitis\n* History of malignant neoplasms within the past 5 years prior to screening\n* Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2\n* Is currently using other medications for weight loss or other GLP-1 receptor agonists\n* Has a history of allergy or sensitivity to Semaglutide\n* Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)\n* Has untreated hypertension with a seated systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg, or heart rate \\> 100 beats\u002Fminute\n* Has current uncontrolled hypertension\n* Has current uncontrolled Type I or Type II diabetes mellitus\n* Has untreated hypothyroidism with a TSH \\> 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit\n* Has active gallbladder disease\n* Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder\n* Has a recent history of substance use disorder (with the exception of cannabis or tobacco use disorder) within the past 12 months\n* Is currently engaging in other treatment for Alcohol Use Disorder or making intentional efforts to quit alcohol use\n* Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device\n* Is breast-feeding, pregnant, or not using a reliable form of birth control\n* Reports active suicidal or homicidal ideation\n* Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria which, in the investigator's opinion, might have jeopardized the participant's safety or compliance with the protocol",{"count":554,"type":22},10,[429],"The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.",[558,29,559],"Alcohol Use Disorder","Bariatric Surgery Patients","2026-05-07",{"date":562,"type":37},"2026-05-12",{"date":564,"type":37},"2026-03-06",{"date":566,"type":22},"2026-10-31",{"name":568,"class":98},"Yale University",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":53,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":576,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":75},"100639615","testing-a-tailored-approach-to-long-term-weight-loss-success-100639615","NCT07577765","Testing a Tailored Approach to Long-Term Weight Loss Success","Pilot Testing an Adaptive Intervention for Weight Loss Maintenance","Inclusion Criteria:\n\n* BMI of ≥ 27 prior to weight loss\n* Lost ≥ 7% of body mass in the past 6 months\n* Weight loss was intentional\n* No plans for weight loss surgery in the next 6 months\n* Access to a smart device that can download applications and receive text messages\n* Able to receive clearance for study participation from primary care provider\n\nExclusion Criteria:\n\n* Pregnant or within 12 months postpartum, or planning pregnancy\n* Uncontrolled conditions that affect overall health (cardiovascular, metabolic, renal, pulmonary, psychiatric, thyroid, cancers)\n* Food insecure\n* Bariatric surgery or cancer treatment within the past 5 years\n* Active or recent (\\\u003C12 months) treatment\u002Fdiagnosis of an eating disorder",{"count":577,"type":22},30,[25],"The purpose of this study is to develop and test an adaptive, individually tailored intervention to prevent weight regain in people who have intentionally lost weight. The main questions it aims to answer are:\n\n* Is an adaptive intervention with tailored re-engagement support feasible for individuals following intentional weight loss?\n* Does this intervention prevent weight regain after intentional weight loss?\n\nParticipants will:\n\n* Complete a baseline assessment of body measurements\n* Complete surveys on dietary intake, mental health, and physical activity\n\nParticipants will also engage in a 26-week program, which involves:\n\n* Receive regular educational texts\u002Femails\n* Fill out weekly online survey check-ins\n* Weigh themselves at least weekly on a scale provided by the study\n* Some participants may receive health coaching during portions of the study.\n* Assessments will be repeated for all participants at the end of the intervention period.",[29,28,308],"2026-05-04",{"date":583,"type":37},"2026-05-11",{"date":585,"type":37},"2026-01-07",{"date":587,"type":22},"2027-09-01",{"name":589,"class":98},"University of Utah",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":106,"minAge":223,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":619,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":632,"leadSponsor":634,"locationsCount":75},"100636706","improved-child-nutrition-and-development-through-social-transfers-100636706","NCT07569172","Improved Child Nutrition and Development Through Social Transfers","Taabo Enhanced Nutrition and Development Through Economic Rewards","TENDER","Inclusion Criteria:\n\n1. Are enrolled in the Taabo multigenerational birth cohort (MGC)\n2. Completed the postpartum interview of the Taabo MGC\n3. Have a child who is within two weeks of their 12-month birthday,\n4. are breastfeeding at time of recruitment,\n5. live in the Taabo HDSS, Côte d'Ivoire\n6. have no illnesses that contraindicates breastfeeding,\n7. had a healthy singleton infant with a birth weight of at least 2500 grams, and\n8. agree to participate and sign an informed consent; if underage (12-17 years), a legal representative will also have to agree to sign the informed consent\n\nExclusion Criteria:\n\n1. Plans to move permanently outside study area\n2. Has a medical, intellectual or psychological disability\n3. Contraindication for breastfeeding\n4. Children born with \\\u003C 2500 grams",{"count":599,"type":22},1040,[25],"The goal of this clinical trial is to learn if a conditional social transfer works to improve rates of complementary breastfeeding. It will also learn about the impacts of social transfers on maternal and child health and development. The main questions it aims to answer are:\n\n* Does the social transfer increase complementary breastfeeding rates at 24-months postpartum?\n* Does the social transfer increase complementary breastfeeding duration?\n* Does the social transfer impact child health and development?\n* Does the social transfer impact maternal physical and mental health?\n\nResearchers will compare a conditional social transfer to a control group that only receives education about breastfeeding recommendations to see if a conditional social transfers works to increase complementary breastfeeding.\n\nParticipants will:\n\nReceive a pamphlet explaining the current recommendations of breastfeeding Receive instructions that if they meet the recommendation to breastfeed until 24-months postpartum they receive a social transfer or receive no additional information Complete home visits at 12- and 24-months postpartum Complete detailed questionnaire",[603,604,605,606,607,608,609,610,611,29,612,613,614,615,616,617,618],"Breastfeeding","Breastfeeding Education","Breastfeeding Duration","Breastfeeding Continuation","Child Growth","Stress","Infectious Diseases","Anemia","Child Development","Blood Pressure","Mental Health","Diarrhea","Coughing","Eczema","Allergies","Antibiotic Use",[620,621,622,623,624,625,626,627],"breastfeeding","cash transfer","child health","maternal health","mental health","child growth","child development","education","2026-04-28",{"date":630,"type":37},"2026-05-06",{"date":435,"type":22},{"date":633,"type":22},"2028-02-28",{"name":635,"class":98},"Swiss Tropical & Public Health Institute",{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":53,"sex":18,"minAge":402,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":23,"phases":645,"briefSummary":646,"conditions":647,"keywords":648,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":75},"100575730","adipocyte-derived-extracellular-vesicles-weight-loss-and-endothelial-function-100575730","NCT06776081","Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function","Adipocyte-Derived Extracellular Vesicles; Novel Biomarker and Mediator of Obesity-Related Endothelial Dysfunction","Inclusion criteria:\n\n* Age ≥40 years\n* BMI \\\u003C25 kg\u002Fm2 and BMI \\>25 kg\u002Fm2 for Phase 1 and BMI \\>25 kg\u002Fm2 for Phase 2. Rationale for defining obesity as BMI \\>25 kg\u002Fm2\n\nExclusion criteria:\n\n* Current smoker\n* Chronic overt medical condition (e.g., evidence of coronary artery disease on resting ECG, any history of myocardial infarction or stroke, or cancer, diabetes based on fasting blood glucose concentration)\n* Alcohol abuse or dependence defined as more than 14 standard drinks\u002Fweek and no more than 4 standard drinks\u002Fday for men and 7 standard drinks\u002Fweek and 3 standard drinks\u002Fday for women (a standard drink is defined as 12 ounces of beer, 5 ounces of wines, 1 ½ ounces of 80-proof distilled spirits) reported during the medical history\u002Fphysical exam\n* Stage III hypertension (systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg)\n* Regular vigorous aerobic\u002Fendurance exercise (\\>3 bouts\u002Fweek, \\>30 minutes\u002Fbout at a workload \\>6 METS)\n* Women who are pregnant or breastfeeding\n* History of anaphylaxis to betadine, lidocaine, iodine\n* Raynaud's disease\n* History of clotting disorders\n* Anyone taking blood thinners and clotting medications\n* Anyone taking statin medication\n* Planned pregnancy in coming 4-6 months",{"count":644,"type":22},84,[25],"Changes in adipose tissue biology are now recognized as a key factor underlying the increased risk of metabolic and cardiovascular disease with obesity. Clinical interest in adipocyte-derived extracellular vesicles (Ad-EVs) has intensified due to their potential as circulating biomarkers of adipose tissue health and systemic messengers, regulators and mediators of cardiometabolic health and disease with obesity.\n\nThe investigators hypothesize that elevated Ad-EVs in adults with obesity will be negatively associated with endothelium-dependent vasodilation. Furthermore, the investigators hypothesize that in adults with obesity, intentional weight loss-induced reduction in circulating Ad-EVs is associated with greater endothelium-dependent vasodilation.",[88,29],[88,29],"2026-04-27",{"date":628,"type":37},{"date":652,"type":37},"2024-07-01",{"date":654,"type":22},"2027-06-30",{"name":656,"class":98},"University of Colorado, Boulder",{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":279,"enrollmentInfo":665,"targetDuration":4,"studyType":227,"phases":4,"briefSummary":667,"conditions":668,"keywords":671,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":686},"100610560","changes-in-taste-and-eating-habits-associated-with-glp-1-agonists-in-weight-loss-patients-100610560","NCT07229170","Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients","Changes in Taste Perception, Eating Habits, and Other Behavioral Aspects Associated With the Use of GLP-1 Receptor Agonists in Patients Undergoing Weight Loss Treatment: A Retrospective Observational Study.","GLP1-TASTE","Inclusion: Adults aged 18-60 years diagnosed with obesity and undergoing treatment with GLP-1 receptor agonists such as semaglutide or tirzepatide. Must have clinical records and dietary data available for at least 12 weeks of treatment.\n\nExclusion: Patients with conditions affecting taste independent of GLP-1 treatment, severe comorbidities, or inability to provide consent and data.",{"count":666,"type":22},150,"This observational retrospective study aims to evaluate changes in taste perception, eating habits, and behavioral aspects in adults treated with GLP-1 receptor agonists for weight loss. Participants include adults aged 18-60 receiving treatment at specialized nutrition centers in Italy. Data are collected from clinical records, dietary questionnaires, and metabolic assessments before and after at least 12 weeks of GLP-1 agonist treatment. The study's primary goal is to understand how these treatments affect food preferences and taste perception. Secondary outcomes include changes in body weight, body composition, gastrointestinal side effects, and treatment adherence. All data are anonymized and collected according to ethical guidelines.",[308,669,29,670],"Taste Alterations","Eating Behavior Changes",[672,673,674,675,676,677],"GLP-1 agonists","Obesity treatment","Weight loss","Taste perception","Eating habits","Observational study","2026-04-22",{"date":628,"type":37},{"date":681,"type":37},"2025-12-01",{"date":683,"type":22},"2028-01-01",{"name":685,"class":98},"San Raffaele Telematic University",4,{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":691,"acronym":692,"eligibilityCriteria":693,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":694,"enrollmentInfo":695,"targetDuration":4,"studyType":227,"phases":4,"briefSummary":697,"conditions":698,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":701,"lastUpdatePostDateStruct":702,"startDateStruct":704,"completionDateStruct":706,"leadSponsor":708,"locationsCount":75},"100400424","endoscopic-bariatric-therapies-ebts-a-retrospective-and-prospective-multicenter-registry-100400424","NCT04494048","Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry","EBT","Inclusion Criteria:\n\n* Any patient who is considering undergoing EBT for weight loss within 6 months, or has undergone clinically indicated EBT for weight loss within the past 6 months\n* Above or equal to 18 years of age.\n\nExclusion Criteria:\n\n* Any patient who has not undergone or will undergo EBT for weight loss\n* Below 18 years of age.","89 Years",{"count":696,"type":22},9999,"The purpose of this registry study is to collect data through medical chart review and in patient visits on the efficacy and safety of various Endoscopic Bariatric therapies (EBTs). This is a retrospective and prospective, observational, medical chart review study for at least 6 standard of care visits up to 1 years after a subject consents for study participation.",[88,29,699,700],"Gastro Esophageal Reflux","Bariatric Surgery Candidate","2026-04-21",{"date":703,"type":37},"2026-04-23",{"date":705,"type":37},"2016-04-05",{"date":707,"type":22},"2035-10-31",{"name":709,"class":98},"Weill Medical College of Cornell University",{"id":711,"slug":712,"hasResults":12,"nctId":713,"briefTitle":714,"officialTitle":714,"acronym":4,"eligibilityCriteria":715,"healthyVolunteers":53,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":716,"targetDuration":4,"studyType":23,"phases":718,"briefSummary":719,"conditions":720,"keywords":722,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":726,"startDateStruct":728,"completionDateStruct":730,"leadSponsor":732,"locationsCount":75},"100604075","family-comida-consumo-de-opciones-ms-ideales-de-alimentos-eating-more-ideal-food-options-100604075","NCT07144800","Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)","Inclusion Criteria:\n\nPhase 1\n\n* Age \\>= 18 years (per self-report)\n* Self-identifies as Hispanic\u002FLatino (per self-report)\n* Seeking, or has used, services at the VDS or MHU (per self-report)\n* Is the parent or primary caregiver for at least one child aged 8-12 living in their household (per self-report)\n* Screens as obese (BMI \\> 30 kg\u002Fm2) or overweight (BMI of 25 - 29.9 kg\u002Fm2) (per height and weight measurement in person or per self-report)\n* Owns a cell phone capable of receiving text messages (per self-report)\n* Owns an internet connected device (e.g. cell phone, tablet, etc.) capable of conducting videoconference calls (per self-report)\n* Agrees to be audio-recorded (per self-report)\n\nPhase 2 (parent participants)\n\n* Age \\>= 18 years (per self-report)\n* Self-identifies as Hispanic\u002FLatino (per self-report)\n* Seeking, or has used, services at the VDS or MHU (per self-report)\n* Is the parent or primary caregiver for at least one child aged 8-12 living in their household (per self-report)\n* Screens as obese (BMI \\> 30 kg\u002Fm2) or overweight (BMI of 25 - 29.9 kg\u002Fm2) (per height and weight measurement in person or remotely)\n* Owns a cell phone capable of receiving text messages (per self-report)\n* Owns an internet connected device (e.g. cell phone, tablet, etc.) capable of conducting videoconference calls (per self-report)\n* Agrees to be audio-recorded (per self-report)\n\nPhase 2 (child participants)\n\n* Age 8-12 years (per parent self-report)\n* Has a parent or primary caregiver who is eligible and participating in Phase 2 (per parent self-report)\n\nExclusion Criteria:\n\nPhase 1\n\n* Is pregnant or might be pregnant (per self-report)\n* Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with hypertension and diabetes mellitus may still participate) that may affect diet and study participation (per self-report)\n* Has dietary restrictions, i.e. liquid diet, that may affect diet and study participation (per self-report)\n* Has a household member who has already participated or agreed to participate in this study program (per self-report)\n* Prior participation in one of our preliminary studies, e.g., COMIDA, SANOS, Family COMIDA (per self-report) and any related focus groups\n* Works for or with the VDS or MHU (per self-report)\n* Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For data collection (per study team)\n\nPhase 2 (parent participant)\n\n* Is pregnant or might be pregnant (per self-report)\n* For women, is lactating (per self-report)\n* Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with hypertension and diabetes mellitus may still participate) that may affect diet and study participation (per self-report)\n* Has dietary restrictions, i.e., liquid diet, that may affect diet and study participation (per self-report)\n* Has physical activity restrictions, i.e., handicapped or mobility issues, that may affect physical activity participation (increasing step counts; per self-report)\n* Has a household member who has already participated or agreed to participate in this study program (per self-report)\n* Prior participation in one of our preliminary studies, e.g., COMIDA, SANOS, Family COMIDA (per self-report) and any related focus groups\n* Works for or with the VDS or MHU (per self-report)\n* Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For data collection (per study team)\n\nPhase 2 (child participant)\n\n* Has dietary restrictions, i.e., liquid diet, that may affect diet and study participation (per parent self-report)\n* Has physical activity restrictions, i.e., handicapped or mobility issues, that may affect physical activity participation (per parent self-report)\n* Has an eating disorder (per parent self-report)\n* Is underweight (per parent self-report)",{"count":717,"type":22},1319,[25],"The purpose of this study is to determine the most effective family-centered intervention (FCI) for weight loss and obesity prevention in Hispanic families. FCI is a type of program that involves family (such as parents and caregivers) supporting their children to promote healthy habits.",[88,721,29],"Child Obesity",[723,138,140,724,725],"child obesity","Memorial Sloan Kettering Cancer Center","25-003",{"date":727,"type":37},"2026-04-15",{"date":729,"type":37},"2025-08-22",{"date":731,"type":22},"2031-07-31",{"name":724,"class":98}]